Barinthus Biotherapeutics plc. (BRNS)
About Barinthus Biotherapeutics plc.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$66.4M
- Total assets
- $98.2M
- Market cap
- $26.6M
- Operating margin
- -13943.7%
- Net margin
- -13134.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $506.0K
- Operating expenses
- $71.1M
- Operating income
- -$70.6M
- Income tax
- -$175.0K
- Net income
- -$66.5M
- EPS (basic)
- $-1.64
- EPS (diluted)
- $-1.64
Balance sheet
- Total assets
- $98.2M
- Current assets
- $77.8M
- Total liabilities
- $23.9M
- Current liabilities
- $10.0M
- Shareholders’ equity
- $74.3M
Cash flow
- Operating cash flow
- -$48.0M
- Investing cash flow
- $416.0K
- Financing cash flow
- $2.0K
- Net cash flow
- -$47.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $26.6M
- EPS (diluted)
- $-1.64
- Shares outstanding
- 44.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 30, 2021
Barinthus Biotherapeutics plc. (BRNS) Stock Price
- Reported a net loss of $66.4M in FY2025.
- Revenue declined 37% from FY2023 to FY2025.
- Trading 70% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Barinthus Biotherapeutics plc..
Write a review
News about Barinthus Biotherapeutics plc.
News & sentiment via Polygon.io
Barinthus Biotherapeutics plc.: frequently asked questions
Is Barinthus Biotherapeutics plc. an American company?
Barinthus Biotherapeutics plc. is a US-based company headquartered in Germantown, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Barinthus Biotherapeutics plc. headquartered?
Barinthus Biotherapeutics plc. is headquartered in Germantown, Maryland, United States.
Is Barinthus Biotherapeutics plc. publicly traded?
Yes — Barinthus Biotherapeutics plc. is a publicly traded company. Its stock trades under the ticker symbol BRNS on the NASDAQ.
What does Barinthus Biotherapeutics plc. do?
Barinthus Biotherapeutics plc. is an American Pharmaceuticals company in the Health & Beauty sector.
